Fulgent Genetics (FLGT) Financials

$20.31 -0.21 (-1.02%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$20.14 -0.17 (-0.84%)

As of 05/23/2025 07:00 PM Eastern

Annual Income Statements for Fulgent Genetics

This table shows Fulgent Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-43	-168	143
Consolidated Net Income / (Loss)	-44	-175	142
Net Income / (Loss) Continuing Operations	-44	-175	142
Total Pre-Tax Income	-52	-174	184
Total Operating Income	-74	-196	179
Total Gross Profit	107	104	367
Total Revenue	283	289	619
Operating Revenue	283	289	619
Total Cost of Revenue	176	185	252
Operating Cost of Revenue	176	185	252
Total Operating Expenses	181	300	188
Selling, General & Admin Expense	88	89	111
Marketing Expense	36	41	39
Research & Development Expense	49	41	29
Amortization Expense	7.97	7.85	6.50
Impairment Charge	0.00	120	0.00
Restructuring Charge	0.00	0.00	2.98
Total Other Income / (Expense), net	22	21	5.50
Interest Expense	-0.17	-	-
Interest & Investment Income	31	22	5.62
Other Income / (Expense), net	-9.51	0.32	0.89
Income Tax Expense	-8.14	1.15	42
Net Income / (Loss) Attributable to Noncontrolling Interest	-1.11	-7.41	-1.48
Weighted Average Basic Shares Outstanding	30.24M	29.78M	30.10M
Weighted Average Diluted Shares Outstanding	30.24M	29.78M	30.96M
Weighted Average Basic & Diluted Shares Outstanding	30.83M	29.78M	29.52M

This table shows Fulgent Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-5.89	-15	-8.71	-13	-128	-13	-11	-15	-24	1.72
Consolidated Net Income / (Loss)	-6.19	-15	-9.09	-14	-134	-13	-12	-16	-24	1.34
Net Income / (Loss) Continuing Operations	-6.19	-15	-9.09	-14	-134	-13	-12	-16	-24	1.34
Total Pre-Tax Income	-8.04	-19	-11	-14	-145	6.86	-15	-21	-33	1.76
Total Operating Income	-16	-17	-19	-22	-151	0.21	-20	-25	-37	0.35
Total Gross Profit	32	27	26	22	25	40	21	19	13	46
Total Revenue	76	72	71	64	71	85	68	66	68	106
Operating Revenue	76	72	71	64	71	85	68	66	68	106
Total Cost of Revenue	44	45	45	42	45	45	47	47	55	60
Operating Cost of Revenue	44	45	45	42	45	45	47	47	55	60
Total Operating Expenses	48	44	45	44	176	40	40	44	50	46
Selling, General & Admin Expense	24	21	21	21	32	17	18	22	29	26
Marketing Expense	9.54	9.12	8.60	8.99	11	10	11	10	10	9.86
Research & Development Expense	12	12	13	11	12	10	9.69	9.78	8.51	7.51
Amortization Expense	1.99	1.99	1.99	1.99	1.96	1.96	1.96	1.97	2.01	2.01
Total Other Income / (Expense), net	8.10	-1.45	7.69	7.63	5.93	6.65	5.10	3.78	3.09	1.41
Interest & Investment Income	7.90	8.09	7.69	7.63	6.27	6.47	5.10	3.78	3.22	1.41
Income Tax Expense	-1.85	-3.84	-2.12	-0.33	-11	20	-3.11	-5.20	-9.39	0.41
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.30	-0.05	-0.38	-0.38	-6.19	-0.36	-0.36	-0.51	-0.24	-0.38
Weighted Average Basic Shares Outstanding	30.24M	30.42M	30.10M	29.77M	29.78M	30.01M	29.81M	29.54M	30.10M	30.17M
Weighted Average Diluted Shares Outstanding	30.24M	30.42M	30.10M	29.77M	29.78M	30.01M	29.81M	29.54M	30.96M	30.87M
Weighted Average Basic & Diluted Shares Outstanding	30.83M	30.59M	30.30M	29.92M	29.78M	29.63M	29.93M	29.70M	29.52M	29.44M

This table details how cash moves in and out of Fulgent Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-42	18	-85
Net Cash From Operating Activities	21	27	254
Net Cash From Continuing Operating Activities	21	27	254
Net Income / (Loss) Continuing Operations	-44	-175	142
Consolidated Net Income / (Loss)	-44	-175	142
Depreciation Expense	25	26	33
Amortization Expense	-5.55	-3.91	4.77
Non-Cash Adjustments To Reconcile Net Income	61	177	60
Changes in Operating Assets and Liabilities, net	-15	2.82	14
Net Cash From Investing Activities	-58	39	-261
Net Cash From Continuing Investing Activities	-58	39	-261
Purchase of Property, Plant & Equipment	-40	-22	-19
Acquisitions	0.00	-0.40	-183
Purchase of Investments	-472	-492	-418
Sale of Property, Plant & Equipment	0.31	0.78	0.41
Sale and/or Maturity of Investments	454	553	373
Other Investing Activities, net	0.00	0.00	-15
Net Cash From Financing Activities	-4.85	-48	-77
Net Cash From Continuing Financing Activities	-4.85	-48	-77
Repayment of Debt	-1.23	-4.27	-0.37
Repurchase of Common Equity	-0.23	-25	-74
Other Financing Activities, net	-3.39	-18	-2.44
Effect of Exchange Rate Changes	-0.06	-0.15	-0.45
Cash Interest Paid	0.51	0.96	0.00
Cash Income Taxes Paid	28	3.26	56

This table details how cash moves in and out of Fulgent Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-2.90	-6.93	10	-43	13	26	-7.82	-13	-89	30
Net Cash From Operating Activities	25	-16	4.29	7.27	15	10	9.74	-7.91	33	21
Net Cash From Continuing Operating Activities	25	-16	4.29	7.27	15	10	9.74	-7.91	33	21
Net Income / (Loss) Continuing Operations	-6.19	-15	-9.09	-14	-134	-13	-12	-16	-24	1.34
Consolidated Net Income / (Loss)	-6.19	-15	-9.09	-14	-134	-13	-12	-16	-24	1.34
Depreciation Expense	6.19	5.92	6.15	6.66	6.53	6.42	6.31	6.88	9.80	9.82
Amortization Expense	-1.55	-1.34	-1.49	-1.18	-1.53	-1.19	-0.71	-0.48	0.54	1.01
Non-Cash Adjustments To Reconcile Net Income	15	19	17	9.77	145	6.67	15	10	6.87	17
Changes in Operating Assets and Liabilities, net	12	-25	-8.16	5.86	-0.76	12	0.24	-8.47	40	-8.58
Net Cash From Investing Activities	-27	8.99	7.30	-47	24	20	-1.10	-4.35	-93	44
Net Cash From Continuing Investing Activities	-27	8.99	7.30	-47	24	20	-1.10	-4.35	-93	44
Purchase of Property, Plant & Equipment	-3.78	-20	-13	-4.06	-3.11	-4.92	-12	-2.03	-4.72	-5.44
Purchase of Investments	-98	-115	-63	-196	-148	-93	-107	-144	-146	-12
Sale and/or Maturity of Investments	75	144	83	152	176	118	117	141	108	61
Net Cash From Financing Activities	-0.33	-0.57	-1.15	-2.81	-26	-4.47	-16	-1.10	-30	-35
Net Cash From Continuing Financing Activities	-0.33	-0.57	-1.15	-2.81	-26	-4.47	-16	-1.10	-30	-35
Other Financing Activities, net	-0.33	-0.57	-0.68	-1.82	-16	14	-15	-1.10	-0.54	-0.76
Effect of Exchange Rate Changes	-0.13	0.16	-0.01	-0.07	0.15	-0.12	-0.21	0.03	-0.28	0.39
Cash Interest Paid	0.05	0.01	0.01	0.44	0.02	0.02	0.92	0.00	-	-
Cash Income Taxes Paid	0.95	25	0.60	1.31	0.56	0.06	0.96	1.68	0.01	1.20

This table presents Fulgent Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	1,220	1,235	1,386
Total Current Assets	354	508	628
Cash & Equivalents	55	97	80
Short-Term Investments	203	327	447
Accounts Receivable	69	51	53
Other Current Assets	26	33	49
Plant, Property, & Equipment, net	106	83	81
Total Noncurrent Assets	761	644	677
Long-Term Investments	570	444	339
Goodwill	22	22	143
Intangible Assets	135	143	151
Other Noncurrent Operating Assets	33	35	44
Total Liabilities & Shareholders' Equity	1,220	1,235	1,386
Total Liabilities	91	102	116
Total Current Liabilities	73	73	88
Short-Term Debt	0.41	1.18	21
Accounts Payable	18	15	23
Accrued Expenses	24	31	25
Customer Deposits	28	23	11
Current Deferred Revenue	2.23	2.87	3.20
Other Current Liabilities	0.00	0.16	5.30
Total Noncurrent Liabilities	18	29	28
Noncurrent Deferred & Payable Income Tax Liabilities	11	14	9.84
Other Noncurrent Operating Liabilities	6.97	15	18
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,129	1,133	1,270
Total Preferred & Common Equity	1,133	1,136	1,267
Preferred Stock	0.00	0.00	0.00
Total Common Equity	1,133	1,136	1,267
Common Stock	543	502	487
Retained Earnings	590	633	801
Accumulated Other Comprehensive Income / (Loss)	-0.37	1.21	-21
Noncontrolling Interest	-4.07	-2.82	3.19

This table presents Fulgent Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,234	1,232	1,230	1,358	1,355	1,377	1,406
Total Current Assets	327	399	387	550	528	581	697
Cash & Equivalents	58	65	55	84	58	66	169
Short-Term Investments	155	247	251	384	400	438	402
Accounts Receivable	57	57	52	49	35	44	104
Other Current Assets	56	31	29	33	35	33	21
Plant, Property, & Equipment, net	107	93	87	85	88	79	82
Total Noncurrent Assets	800	740	757	723	739	717	627
Long-Term Investments	602	547	561	399	401	380	358
Goodwill	22	22	22	142	142	143	120
Intangible Assets	137	139	141	144	146	149	88
Other Noncurrent Operating Assets	39	32	33	38	49	45	61
Total Liabilities & Shareholders' Equity	1,234	1,232	1,230	1,358	1,355	1,377	1,406
Total Liabilities	99	103	103	97	91	108	124
Total Current Liabilities	74	76	76	61	65	82	103
Short-Term Debt	0.41	0.41	0.41	2.89	4.56	5.61	20
Accounts Payable	20	20	20	16	21	22	14
Accrued Expenses	24	26	26	21	22	21	25
Customer Deposits	27	26	27	19	14	12	26
Current Deferred Revenue	2.97	2.74	2.76	2.59	2.60	2.73	2.60
Other Current Liabilities	0.00	0.00	0.00	0.28	0.36	19	14
Total Noncurrent Liabilities	25	28	27	35	26	26	22
Noncurrent Deferred & Payable Income Tax Liabilities	13	13	13	19	9.84	9.84	1.83
Other Noncurrent Operating Liabilities	12	14	14	16	17	16	20
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,135	1,129	1,127	1,262	1,263	1,269	1,281
Total Preferred & Common Equity	1,138	1,133	1,130	1,259	1,260	1,264	1,277
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,138	1,133	1,130	1,259	1,260	1,264	1,277
Common Stock	533	522	511	514	506	496	478
Retained Earnings	596	611	620	761	774	786	825
Accumulated Other Comprehensive Income / (Loss)	9.18	-0.88	-1.10	-17	-21	-17	-26
Noncontrolling Interest	-3.55	-3.70	-3.30	3.14	3.56	4.47	4.35

This table displays calculated financial ratios and metrics derived from Fulgent Genetics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-1.99%	-53.28%	-37.64%
EBITDA Growth	62.97%	-179.77%	-68.78%
EBIT Growth	57.26%	-208.80%	-73.46%
NOPAT Growth	62.20%	-199.41%	-72.55%
Net Income Growth	74.99%	-223.47%	-71.97%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-22.01%	-89.35%	-52.93%
Free Cash Flow Firm Growth	-492.19%	146.06%	-111.56%
Invested Capital Growth	13.07%	-37.38%	77.44%
Revenue Q/Q Growth	2.06%	0.98%	-22.91%
EBITDA Q/Q Growth	66.14%	-223.97%	-45.60%
EBIT Q/Q Growth	60.06%	-141.12%	-50.97%
NOPAT Q/Q Growth	64.62%	-141.51%	-48.61%
Net Income Q/Q Growth	74.52%	-169.68%	-47.37%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	91.89%	-40.36%	-14.75%
Free Cash Flow Firm Q/Q Growth	-27.02%	126.87%	-198.91%
Invested Capital Q/Q Growth	-5.90%	-33.11%	14.12%
Profitability Metrics	-	-	-
Gross Margin	37.82%	36.12%	59.28%
EBITDA Margin	-22.60%	-59.81%	35.03%
Operating Margin	-26.08%	-67.61%	28.84%
EBIT Margin	-29.43%	-67.50%	28.99%
Profit (Net Income) Margin	-15.46%	-60.59%	22.93%
Tax Burden Percent	84.34%	100.66%	77.12%
Interest Burden Percent	62.28%	89.18%	102.57%
Effective Tax Rate	0.00%	0.00%	22.88%
Return on Invested Capital (ROIC)	-18.24%	-39.58%	41.41%
ROIC Less NNEP Spread (ROIC-NNEP)	-19.17%	-35.10%	40.94%
Return on Net Nonoperating Assets (RNNOA)	14.36%	25.00%	-29.76%
Return on Equity (ROE)	-3.87%	-14.58%	11.65%
Cash Return on Invested Capital (CROIC)	-30.51%	6.38%	-14.41%
Operating Return on Assets (OROA)	-6.80%	-14.89%	13.47%
Return on Assets (ROA)	-3.57%	-13.37%	10.65%
Return on Common Equity (ROCE)	-3.89%	-14.58%	11.60%
Return on Equity Simple (ROE_SIMPLE)	-3.87%	-15.42%	11.20%
Net Operating Profit after Tax (NOPAT)	-52	-137	138
NOPAT Margin	-18.25%	-47.33%	22.24%
Net Nonoperating Expense Percent (NNEP)	0.93%	-4.48%	0.48%
Return On Investment Capital (ROIC_SIMPLE)	-4.58%	-12.06%	10.67%
Cost of Revenue to Revenue	62.18%	63.88%	40.72%
SG&A Expenses to Revenue	31.08%	30.77%	17.95%
R&D to Revenue	17.22%	14.33%	4.67%
Operating Expenses to Revenue	63.90%	103.72%	30.43%
Earnings before Interest and Taxes (EBIT)	-83	-195	179
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-64	-173	217
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.50	0.75	0.69
Price to Tangible Book Value (P/TBV)	0.58	0.88	0.90
Price to Revenue (P/Rev)	1.99	2.96	1.42
Price to Earnings (P/E)	0.00	0.00	6.11
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	16.36%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.08
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.06
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.16
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.20
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.26
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.14
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.02
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.75	-0.71	-0.73
Leverage Ratio	1.09	1.09	1.09
Compound Leverage Factor	0.68	0.97	1.12
Debt to Total Capital	0.04%	0.10%	1.60%
Short-Term Debt to Total Capital	0.04%	0.10%	1.60%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.36%	-0.25%	0.25%
Common Equity to Total Capital	100.32%	100.14%	98.15%
Debt to EBITDA	-0.01	-0.01	0.10
Net Debt to EBITDA	12.93	5.01	-3.90
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	-0.01	-0.01	0.15
Net Debt to NOPAT	16.00	6.33	-6.13
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	4.69	5.89	6.68
Noncontrolling Interest Sharing Ratio	-0.30%	0.02%	0.42%
Liquidity Ratios	-	-	-
Current Ratio	4.85	6.96	7.13
Quick Ratio	4.49	6.51	6.57
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-87	22	-48
Operating Cash Flow to CapEx	52.65%	125.99%	1,380.60%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.23	0.22	0.46
Accounts Receivable Turnover	4.72	5.57	6.46
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	3.00	3.51	8.62
Accounts Payable Turnover	10.45	9.61	11.57
Days Sales Outstanding (DSO)	77.36	65.55	56.51
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	34.92	37.98	31.56
Cash Conversion Cycle (CCC)	42.44	27.57	24.95
Capital & Investment Metrics	-	-	-
Invested Capital	301	266	425
Invested Capital Turnover	1.00	0.84	1.86
Increase / (Decrease) in Invested Capital	35	-159	186
Enterprise Value (EV)	-267	-13	35
Market Capitalization	565	857	877
Book Value per Share	$37.05	$38.34	$43.03
Tangible Book Value per Share	$31.92	$32.77	$33.05
Total Capital	1,130	1,134	1,291
Total Debt	0.41	1.18	21
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-828	-867	-845
Capital Expenditures (CapEx)	40	21	18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	23	12	34
Debt-free Net Working Capital (DFNWC)	281	436	560
Net Working Capital (NWC)	281	435	540
Net Nonoperating Expense (NNE)	-7.92	38	-4.24
Net Nonoperating Obligations (NNO)	-828	-867	-845
Total Depreciation and Amortization (D&A)	19	22	37
Debt-free, Cash-free Net Working Capital to Revenue	8.11%	4.10%	5.52%
Debt-free Net Working Capital to Revenue	99.16%	150.76%	90.54%
Net Working Capital to Revenue	99.01%	150.35%	87.20%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	30.24M	29.78M	0.00
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	30.24M	29.78M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	30.83M	29.78M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-52	-53	140
Normalized NOPAT Margin	-18.25%	-18.22%	22.61%
Pre Tax Income Margin	-18.33%	-60.19%	29.73%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.51%	-14.30%	52.38%

This table displays calculated financial ratios and metrics derived from Fulgent Genetics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.10%	-15.28%	4.68%	-2.54%	4.14%	-19.85%	-45.87%	-79.34%	-73.10%	-53.63%
EBITDA Growth	92.14%	-487.25%	-0.27%	11.42%	-457.42%	-49.13%	-163.25%	-108.83%	-116.75%	-93.22%
EBIT Growth	89.32%	-5,909.61%	4.51%	12.19%	-313.44%	30.11%	-254.74%	-112.29%	-124.23%	-99.78%
NOPAT Growth	89.32%	-2,745.98%	4.51%	12.19%	-313.44%	-256.13%	-234.21%	-111.32%	-124.67%	-99.78%
Net Income Growth	95.39%	-9.12%	21.57%	12.64%	-457.96%	-1,102.68%	-204.42%	-110.32%	-123.22%	-98.90%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	67.54%	-251.46%	-55.99%	191.89%	-55.03%	-50.71%	-12.48%	-104.20%	-56.92%	-86.35%
Free Cash Flow Firm Growth	-186.73%	355.50%	355.41%	162.09%	125.17%	88.19%	77.26%	-634.00%	-1,373.31%	-533.41%
Invested Capital Growth	13.07%	-19.62%	-33.63%	-33.26%	-37.38%	6.83%	9.29%	74.88%	77.44%	143.34%
Revenue Q/Q Growth	6.23%	1.01%	10.15%	-8.54%	-16.75%	24.81%	2.55%	-2.27%	-35.92%	-15.71%
EBITDA Q/Q Growth	47.84%	-54.67%	12.75%	88.83%	-2,669.32%	140.05%	22.92%	29.72%	-334.48%	-50.21%
EBIT Q/Q Growth	39.36%	-40.74%	13.27%	85.58%	-33,095.85%	102.31%	20.25%	32.09%	-10,484.09%	-97.25%
NOPAT Q/Q Growth	5.53%	9.66%	13.27%	85.58%	-25,082.25%	96.97%	20.25%	32.09%	-9,609.60%	-97.39%
Net Income Q/Q Growth	57.87%	-61.65%	34.35%	89.69%	-897.58%	-16.19%	26.87%	34.17%	-1,892.70%	-87.90%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	261.31%	-461.94%	-41.03%	-51.34%	45.83%	5.17%	223.14%	-123.81%	59.83%	86.73%
Free Cash Flow Firm Q/Q Growth	-169.70%	-46.68%	8.30%	115.48%	305.33%	46.70%	73.67%	12.65%	3.67%	-2.63%
Invested Capital Q/Q Growth	-5.90%	18.11%	4.04%	-2.21%	-33.11%	-2.48%	4.61%	-8.23%	14.12%	-0.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	41.79%	37.32%	37.30%	34.28%	35.78%	47.05%	30.32%	28.43%	19.18%	43.63%
EBITDA Margin	-15.07%	-30.70%	-20.05%	-25.31%	-207.24%	6.72%	-20.93%	-27.84%	-38.72%	10.58%
Operating Margin	-21.17%	-23.81%	-26.62%	-33.80%	-214.34%	0.25%	-29.18%	-37.52%	-53.99%	0.33%
EBIT Margin	-21.17%	-37.09%	-26.62%	-33.80%	-214.34%	0.54%	-29.18%	-37.52%	-53.99%	0.33%
Profit (Net Income) Margin	-8.12%	-20.48%	-12.80%	-21.47%	-190.53%	-15.90%	-17.08%	-23.95%	-35.56%	1.27%
Tax Burden Percent	77.02%	79.29%	81.06%	97.69%	92.52%	-196.30%	78.84%	75.30%	71.95%	76.44%
Interest Burden Percent	49.81%	69.65%	59.31%	65.02%	96.08%	1,497.82%	74.25%	84.79%	91.55%	499.15%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	296.30%	0.00%	0.00%	0.00%	23.56%
Return on Invested Capital (ROIC)	-14.81%	-12.89%	-15.95%	-20.91%	-125.50%	-0.37%	-16.06%	-31.24%	-70.36%	0.78%
ROIC Less NNEP Spread (ROIC-NNEP)	-15.41%	-12.56%	-16.43%	-21.07%	-122.16%	1.10%	-16.31%	-31.40%	-70.53%	0.66%
Return on Net Nonoperating Assets (RNNOA)	11.54%	8.80%	11.77%	15.35%	87.01%	-0.77%	11.36%	23.94%	51.28%	-0.51%
Return on Equity (ROE)	-3.26%	-4.09%	-4.18%	-5.56%	-38.49%	-1.14%	-4.70%	-7.30%	-19.08%	0.27%
Cash Return on Invested Capital (CROIC)	-30.51%	-18.98%	0.93%	-1.52%	6.38%	-21.31%	-23.35%	-65.49%	-14.41%	18.43%
Operating Return on Assets (OROA)	-4.89%	-7.95%	-5.98%	-7.46%	-47.30%	0.11%	-6.37%	-9.63%	-25.08%	0.20%
Return on Assets (ROA)	-1.88%	-4.39%	-2.88%	-4.74%	-42.04%	-3.30%	-3.73%	-6.15%	-16.52%	0.78%
Return on Common Equity (ROCE)	-3.27%	-4.09%	-4.18%	-5.56%	-38.48%	-1.13%	-4.68%	-7.27%	-19.00%	0.27%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-15.11%	-15.08%	-15.33%	0.00%	-5.16%	-3.98%	-2.17%	0.00%	21.12%
Net Operating Profit after Tax (NOPAT)	-11	-12	-13	-15	-106	-0.42	-14	-17	-26	0.27
NOPAT Margin	-14.82%	-16.66%	-18.63%	-23.66%	-150.04%	-0.50%	-20.42%	-26.26%	-37.79%	0.25%
Net Nonoperating Expense Percent (NNEP)	0.60%	-0.33%	0.48%	0.16%	-3.34%	-1.47%	0.25%	0.16%	0.17%	0.12%
Return On Investment Capital (ROIC_SIMPLE)	-1.00%	-	-	-	-9.32%	-	-	-	-1.98%	-
Cost of Revenue to Revenue	58.21%	62.68%	62.70%	65.72%	64.22%	52.95%	69.68%	71.57%	80.82%	56.37%
SG&A Expenses to Revenue	31.94%	29.20%	30.02%	33.32%	44.97%	20.66%	26.52%	32.95%	42.53%	24.86%
R&D to Revenue	15.89%	16.42%	18.99%	17.73%	16.95%	11.82%	14.28%	14.78%	12.57%	7.11%
Operating Expenses to Revenue	62.96%	61.12%	63.91%	68.08%	250.12%	46.80%	59.50%	65.95%	73.17%	43.29%
Earnings before Interest and Taxes (EBIT)	-16	-27	-19	-22	-151	0.46	-20	-25	-37	0.35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	-22	-14	-16	-146	5.69	-14	-18	-26	11
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.50	0.58	0.52	0.57	0.75	0.64	0.87	0.73	0.69	0.90
Price to Tangible Book Value (P/TBV)	0.58	0.67	0.60	0.67	0.88	0.82	1.13	0.95	0.90	1.08
Price to Revenue (P/Rev)	1.99	2.37	2.02	2.24	2.96	2.79	3.58	2.53	1.42	1.44
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.11	4.25
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16.36%	23.54%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.61	0.12	0.08	0.67
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.81	0.13	0.06	0.31
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.16	0.63
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.68
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.26	0.93
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	4.45	0.83	0.14	0.84
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.15
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.02
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.75	-0.70	-0.72	-0.73	-0.71	-0.70	-0.70	-0.76	-0.73	-0.77
Leverage Ratio	1.09	1.08	1.08	1.09	1.09	1.09	1.09	1.10	1.09	1.12
Compound Leverage Factor	0.54	0.75	0.64	0.71	1.05	16.28	0.81	0.93	1.00	5.60
Debt to Total Capital	0.04%	0.04%	0.04%	0.04%	0.10%	0.23%	0.36%	0.44%	1.60%	1.57%
Short-Term Debt to Total Capital	0.04%	0.04%	0.04%	0.04%	0.10%	0.23%	0.36%	0.44%	1.60%	1.57%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.36%	-0.31%	-0.33%	-0.29%	-0.25%	0.25%	0.28%	0.35%	0.25%	0.33%
Common Equity to Total Capital	100.32%	100.28%	100.29%	100.26%	100.14%	99.52%	99.36%	99.21%	98.15%	98.09%
Debt to EBITDA	-0.01	0.00	0.00	0.00	-0.01	-0.05	-0.10	-0.51	0.10	0.05
Net Debt to EBITDA	12.93	4.31	5.01	5.06	5.01	16.18	17.94	79.84	-3.90	-2.28
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.01	0.00	0.00	0.00	-0.01	-0.05	-0.08	-0.17	0.15	0.08
Net Debt to NOPAT	16.00	5.57	6.40	6.43	6.33	15.24	15.11	26.03	-6.13	-3.39
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	4.88	5.07	4.60	4.92	6.01	6.40	8.62	6.57	6.16	7.47
Noncontrolling Interest Sharing Ratio	-0.30%	-0.02%	-0.01%	0.05%	0.02%	0.29%	0.37%	0.44%	0.42%	0.52%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.85	4.41	5.27	5.09	6.96	8.95	8.15	7.09	7.13	6.79
Quick Ratio	4.49	3.65	4.86	4.71	6.51	8.42	7.61	6.69	6.57	6.59
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-46	66	124	115	53	-26	-49	-184	-211	-219
Operating Cash Flow to CapEx	662.20%	-79.54%	33.15%	191.31%	538.90%	208.94%	81.66%	-430.66%	729.82%	398.54%
Free Cash Flow to Firm to Interest Expense	0.00	4,724.34	0.00	0.00	0.00	-369.82	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-1,107.79	0.00	0.00	0.00	146.29	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-2,500.57	0.00	0.00	0.00	76.27	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.23	0.21	0.22	0.22	0.22	0.21	0.22	0.26	0.46	0.62
Accounts Receivable Turnover	4.72	5.21	6.36	6.01	5.57	3.73	3.66	3.58	6.46	7.14
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	3.00	2.89	3.21	3.47	3.51	3.43	3.54	4.94	8.62	11.31
Accounts Payable Turnover	10.45	9.96	8.75	8.62	9.61	12.84	7.24	9.69	11.57	13.19
Days Sales Outstanding (DSO)	77.36	70.04	57.37	60.68	65.55	97.77	99.81	101.94	56.51	51.14
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	34.92	36.65	41.73	42.33	37.98	28.43	50.42	37.68	31.56	27.67
Cash Conversion Cycle (CCC)	42.44	33.39	15.64	18.36	27.57	69.34	49.39	64.26	24.95	23.46
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	301	320	271	260	266	398	408	390	425	373
Invested Capital Turnover	1.00	0.77	0.86	0.88	0.84	0.74	0.79	1.19	1.86	3.05
Increase / (Decrease) in Invested Capital	35	-78	-137	-130	-159	25	35	167	186	220
Enterprise Value (EV)	-267	-160	-274	-226	-13	-60	248	47	35	249
Market Capitalization	565	658	587	643	857	800	1,100	922	877	1,154
Book Value per Share	$37.05	$37.58	$37.85	$37.96	$38.34	$42.06	$42.41	$42.84	$43.03	$42.19
Tangible Book Value per Share	$31.92	$32.32	$32.47	$32.48	$32.77	$32.49	$32.70	$32.95	$33.05	$35.32
Total Capital	1,130	1,135	1,129	1,127	1,134	1,265	1,268	1,275	1,291	1,302
Total Debt	0.41	0.41	0.41	0.41	1.18	2.89	4.56	5.61	21	20
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-828	-815	-858	-866	-867	-864	-855	-879	-845	-909
Capital Expenditures (CapEx)	3.78	19	13	3.80	2.77	4.90	12	1.84	4.55	5.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	23	40	12	5.28	12	24	9.60	-0.09	34	44
Debt-free Net Working Capital (DFNWC)	281	253	324	311	436	491	468	504	560	615
Net Working Capital (NWC)	281	253	323	311	435	488	463	499	540	594
Net Nonoperating Expense (NNE)	-5.10	2.74	-4.14	-1.41	29	13	-2.27	-1.53	-1.51	-1.07
Net Nonoperating Obligations (NNO)	-828	-815	-858	-866	-867	-864	-855	-879	-845	-909
Total Depreciation and Amortization (D&A)	4.65	4.59	4.67	5.48	5.00	5.23	5.60	6.40	10	11
Debt-free, Cash-free Net Working Capital to Revenue	8.11%	14.36%	4.15%	1.84%	4.10%	8.21%	3.12%	-0.03%	5.52%	5.42%
Debt-free Net Working Capital to Revenue	99.16%	91.07%	111.37%	108.15%	150.76%	171.54%	152.26%	138.24%	90.54%	76.54%
Net Working Capital to Revenue	99.01%	90.92%	111.23%	108.01%	150.35%	170.54%	150.78%	136.70%	87.20%	73.99%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	30.24M	30.42M	30.10M	29.77M	29.78M	30.01M	29.81M	29.54M	30.10M	30.17M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	30.24M	30.42M	30.10M	29.77M	29.78M	30.01M	29.81M	29.54M	30.96M	30.87M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	30.83M	30.59M	30.30M	29.92M	29.78M	29.63M	29.93M	29.70M	29.52M	29.44M
Normalized Net Operating Profit after Tax (NOPAT)	-11	-12	-13	-15	-106	0.15	-14	-17	-26	0.35
Normalized NOPAT Margin	-14.82%	-16.66%	-18.63%	-23.66%	-150.04%	0.18%	-20.42%	-26.26%	-37.82%	0.33%
Pre Tax Income Margin	-10.55%	-25.83%	-15.79%	-21.98%	-205.94%	8.10%	-21.66%	-31.81%	-49.42%	1.66%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-1,900.57	0.00	0.00	0.00	6.54	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-853.95	0.00	0.00	0.00	-6.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-3,293.36	0.00	0.00	0.00	-63.47	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-2,246.74	0.00	0.00	0.00	-76.02	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.51%	-13.43%	-14.81%	-14.60%	-14.30%	-48.10%	-127.08%	-270.48%	52.38%	16.79%

Frequently Asked Questions About Fulgent Genetics' Financials

When does Fulgent Genetics's financial year end?

According to the most recent income statement we have on file, Fulgent Genetics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Fulgent Genetics' net income changed over the last 2 years?

Fulgent Genetics' net income appears to be on an upward trend, with a most recent value of -$43.82 million in 2024, falling from $141.92 million in 2022. The previous period was -$175.24 million in 2023. See where experts think Fulgent Genetics is headed by visiting Fulgent Genetics' forecast page.

What is Fulgent Genetics's operating income?

Fulgent Genetics's total operating income in 2024 was -$73.92 million, based on the following breakdown:

Total Gross Profit: $107.22 million
Total Operating Expenses: $181.13 million

How has Fulgent Genetics revenue changed over the last 2 years?

Over the last 2 years, Fulgent Genetics' total revenue changed from $618.97 million in 2022 to $283.47 million in 2024, a change of -54.2%.

How much debt does Fulgent Genetics have?

Fulgent Genetics' total liabilities were at $90.81 million at the end of 2024, a 11.0% decrease from 2023, and a 21.8% decrease since 2022.

How much cash does Fulgent Genetics have?

In the past 2 years, Fulgent Genetics' cash and equivalents has ranged from $55.14 million in 2024 to $97.47 million in 2023, and is currently $55.14 million as of their latest financial filing in 2024.

How has Fulgent Genetics' book value per share changed over the last 2 years?

Over the last 2 years, Fulgent Genetics' book value per share changed from 43.03 in 2022 to 37.05 in 2024, a change of -13.9%.

Related Companies

This page (NASDAQ:FLGT) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulgent Genetics (FLGT) Financials

Frequently Asked Questions About Fulgent Genetics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulgent Genetics (FLGT) Financials

Annual Income Statements for Fulgent Genetics

Quarterly Income Statements for Fulgent Genetics

Annual Cash Flow Statements for Fulgent Genetics

Quarterly Cash Flow Statements for Fulgent Genetics

Annual Balance Sheets for Fulgent Genetics

Quarterly Balance Sheets for Fulgent Genetics

Annual Metrics And Ratios for Fulgent Genetics

Quarterly Metrics And Ratios for Fulgent Genetics

Frequently Asked Questions About Fulgent Genetics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools